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Acute Reduction of Arterial Inﬂammation
FDG-PET as an Imaging Biomarker of
Nonpharmacological Effects on the Vessel Wall*Sotirios Tsimikas, MDSEE PAGE 1418M olecular imaging is broadly deﬁned as atechnique that incorporates targeted con-trast agents into available imaging modal-
ities to detect and quantitate molecular, cellular,
biological, and physiological pathways relevant to
atherogenesis and cardiovascular disease (CVD)
(1,2). The main forces driving development of
molecular imaging techniques have been the discon-
nect between quantiﬁcation of anatomic atheroscle-
rotic disease and their pathological and histological
characteristics of plaque vulnerability, a need to bet-
ter predict acute clinical syndromes, and the difﬁ-
culty in predicting acute events based on size of
individual lesions. Therefore, anatomic and func-
tional techniques may provide a complementary
approach to imaging high-risk lesions to better un-
derstand their biological properties and clinical
consequences.
Of the many molecular imaging techniques that
are being evaluated or in clinical use, 18F-ﬂuo-
rodeoxyglucose positron emission tomography (FDG-
PET) has the largest clinical experience. FDG is a
glucose isomer that is taken up by metabolically
active cells, such as cancer cells and macrophages.
In animal models of CVD, FDG uptake correlates
with the presence of activated macrophages and is
proportional to the extent of chronic inﬂammation*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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ceuticals during his sabbatical leave.(3). Recent cell culture evidence also points to the
possibility that FDG cellular uptake may reﬂect
hypoxia-stimulated processes rather than inﬂamma-
tion (4). Irrespective of the mechanism, the FDG-PET
imaging studies to date generally reﬂect clinical
expression of CVD. For example, FDG uptake has
been shown to be associated with the presence of
carotid and aortic atherosclerosis and is reduced
with statin therapy (5). By contrast, recent FDG-PET
studies with cholesteryl ester transfer protein and
lipoprotein-associated phospholipase A2 (Lp-PLA2)
inhibitors have largely reﬂected the failure of the
subsequent clinical trials (6,7).In this issue of the Journal, van Wijk et al. (8) eval-
uated the effect of lipoprotein apheresis and its asso-
ciation with aortic and carotid artery inﬂammation.
The target-to-background ratio (TBR) of FDG-PET up-
take was measured in 38 subjects, 24 with familial
hypercholesterolemia (FH) and 14 normolipidemic
controls. Twelve of the FH patients had TBR assessed
at baseline and again after undergoing lipoprotein
apheresis 3 days later. The FH patients had a higher
mean TBR compared with healthy controls and a
modest, but signiﬁcant, correlation was present be-
tween baseline arterial TBR and low-density lipopro-
tein cholesterol (LDL-C) levels. Themain ﬁnding of the
study is that FH patients experienced a signiﬁcant
reduction in TBR to the level of normolipidemic con-
trols following only a single apheresis session.
This study provides 3 important insights: 1) it de-
monstrates for the ﬁrst time the rapid attenuation of
vascular wall inﬂammation of a nonpharmacological
approach by an imaging technique; 2) it reﬂects the role
of apolipoprotein B (apoB)-containing lipoproteins
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low-density lipoprotein] in inﬂammatory pathways
that can be rapidly reversed when they are removed
from the circulation; and 3) it suggests that vessel
wall inﬂammation is likely a downstream effect of the
accumulation and modiﬁcation of apoB-containing
lipoproteins. The chemical modiﬁcation of lipopro-
teins in the vessel wall generates neoepitopes that
act as danger-associated molecular patterns, such as
oxidation-speciﬁc epitopes present on oxidized lipo-
proteins, cell membranes, and apoptotic cells, trig-
gering activation of the innate and adaptive system,
whose response is to generate inﬂammation (9).
Several caveats should be noted in interpreting this
study. First, this is a pilot study that needs to be
conﬁrmed in larger datasets that will afford better
matching of clinical characteristics. Second, patients
had FH with elevated LDL-C, and many were statin
intolerant; therefore, extrapolation to more modest
LDL-C levels cannot be made. Finally, complete data
on high-sensitivity C-reactive protein, Lp(a), and other
inﬂammatory biomarkers were not available; thus any
mechanisms of TBR reduction beyond lowering of
apoB-containing lipoproteins cannot be inferred.
WHAT IS THE CLINICAL EFFICACY AND OUTCOMES
OF LDL APHERESIS? The various methods of lipo-
protein apheresis share the commonality of removing
apoB-containing lipoproteins, which include very-
low-density lipoprotein and triglyceride-rich rem-
nants, and LDL and Lp(a) (10). In the United States,
lipoprotein apheresis is approved for patients with
the severe hypercholesterolemia phenotype (11) on
maximally tolerated therapy with LDL-C >300 mg/dl
or LDL-C >200 mg/dl and the presence of coronary
artery disease. Lipoprotein apheresis results in sig-
niﬁcant reduction of LDL-C and Lp(a) ranging from
50% to 80% in 1 session, often reducing LDL-C from
>200 to <50 mg/dl. However, as a result of both
enhanced synthesis and reduced hepatic clearance of
LDL particles (11), the LDL-C returns to baseline within
1 to 2 weeks, so the time-averaged LDL-C reduction is
w40%, in line with a modestly potent statin. Although
we have no randomized trials in patients on apheresis,
retrospective data in FH patients document signiﬁ-
cant reduction in cardiovascular events with statin
therapy and with apheresis, even with modest re-
ductions in LDL-C (10).IS THE PUTATIVE REDUCTION IN INFLAMMATION
DUE TO LDL-C AND Lp(a) LOWERING, OR IS THERE
AN INTERMEDIARY EFFECT NOT REFLECTED BY
THESE LIPOPROTEINS? There have been several
studies documenting salutary effects of lipoprotein
apheresis on vascular function, often involving a
single LDL apheresis session, including acute
improvement in brachial artery reactivity (12),
endothelium-dependent coronary reactivity (13),
coronary blood ﬂow as measured by 13N-ammonia
(14), and intravascular ultrasound–detected coronary
atheroma regression (15). Additionally, a recent study
has provided mechanistic data demonstrating that
apheresis reduced Lp(a) and its associated oxidized
phospholipids, and Lp-PLA2 mass, but with an in-
crease in Lp-PLA2–speciﬁc activity (16). Because Lp(a)
levels in FH patients are generally 2-fold higher
than in non-FH patients, these effects may contribute
to the beneﬁt of apheresis. Two recent observa-
tional studies provided evidence that patients with
elevated Lp(a) undergoing apheresis had substan-
tially reduced events after apheresis compared with
before apheresis (17,18).
In conclusion, van Wijk et al. (8) should be
congratulated on performing this unique trans-
lational study that takes advantage of a therapeutic
technique coupled to an imaging technique to pro-
vide insights into acute plaque biology. Because
apheresis has been shown to reduce cardiovascular
events in patients who have both high LDL-C and
high Lp(a), one could hypothesize that the FDG
signal reduction noted here should reﬂect the clin-
ical beneﬁt in patients with appropriate responses.
Future studies, such as the PREMIER (Plaque
Regression and Progenitor Cell Mobilization with
Intensive Lipid Elimination Regimen) trial (19), us-
ing virtual histology intravascular ultrasound with
apheresis may provide additional insights into the
effect of apheresis in patients with the most
vulnerable plaques, those with acute coronary
syndromes.
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